Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
BridgeBio Pharma Inc(BBIO)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for BBIO
10/28/2026: BBIO (3-star) is currently NOT-A-BUY. Pass it for now.
BridgeBio Pharma is a clinical-stage biotechnology company that has transitioned into a commercial-stage firm focused on genetic diseases and precision oncology. The company's primary strength lies in its hub-and-spoke R&D model, which has allowed for a diverse and potentially high-value pipeline. Its main growth opportunity centers on the successful commercialization of Acoramidis for ATTR-cardiomyopathy, balanced against intense competition from established pharmaceutical players. Investors must weigh the potential for significant clinical milestones against risks, including high cash consumption and regulatory hurdles. The stock is best suited for growth-oriented investors with a high risk tolerance, who should closely monitor ongoing commercial launch performance and clinical data updates.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company offers exposure to high-growth potential in the precision medicine and rare disease sectors. |
| Momentum investor | Mixed fit | Stock price movement is highly dependent on clinical trial results and regulatory news flow. |
| Value investor | Weak fit | The company is not currently focused on traditional value metrics like P/E ratios or dividend yields. |
| Dividend investor | Weak fit | BridgeBio does not pay a dividend as it reinvests all capital into R&D. |
| Low-risk investor | Weak fit | The inherent risks of drug development make this an unsuitable choice for risk-averse portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical data readouts often lead to significant short-term stock price swings. |
| Valuation risk | Medium / high | Valuations are heavily based on future success of pipeline drugs, which is inherently uncertain. |
| Competition risk (Rare Disease/Oncology) | High | Major players like Pfizer provide intense competition for market share in key therapeutic areas. |
| Business quality | Medium | The hub-and-spoke model is innovative but depends heavily on disciplined execution across many projects. |
| Dividend income | Low / none | This stock does not provide an income stream for investors. |
| Execution risk | High | Success requires complex clinical trials and effective commercial launches for multiple drugs. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 18.2% | Avg. Invested days 44 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/28/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 13.56B USD | Price to earnings Ratio - | 1Y Target Price 107.81 |
Price to earnings Ratio - | 1Y Target Price 107.81 | ||
Volume (30-day avg) 2.8M shares | Beta 0.97 | 52 Weeks Range 60.22 - 93.42 | Updated Date 10/28/2026 |
52 Weeks Range 60.22 - 93.42 | Updated Date 10/28/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.62 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Product Revenue | Sales of FDA-approved therapies such as Acoramidis and other commercialized assets. | Revenue is currently driven by the initial commercial launch of new medicines. |
| Licensing and Collaborations | Upfront payments, milestones, and royalties from partner pharmaceutical companies. | Strategic partnerships provide non-dilutive capital to fund ongoing research. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 15.10B | Price to Sales(TTM) 19.02 |
Enterprise Value 15.10B | Price to Sales(TTM) 19.02 | ||
Enterprise Value to Revenue 21.18 | Enterprise Value to EBITDA -9.4 | Shares Outstanding 195.49M | Shares Floating 167.19M |
Shares Outstanding 195.49M | Shares Floating 167.19M | ||
Percent Insiders 3.91 | Percent Institutions 99.5 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.